Kynam Capital Management, LP Celldex Therapeutics, Inc. Transaction History
Kynam Capital Management, LP
- $1.58 Billion
- Q4 2024
A detailed history of Kynam Capital Management, LP transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Kynam Capital Management, LP holds 5,064,207 shares of CLDX stock, worth $114 Million. This represents 8.11% of its overall portfolio holdings.
Number of Shares
5,064,207
Previous 3,458,609
46.42%
Holding current value
$114 Million
Previous $117 Million
8.92%
% of portfolio
8.11%
Previous 9.64%
Shares
13 transactions
Others Institutions Holding CLDX
# of Institutions
197Shares Held
69.7MCall Options Held
960KPut Options Held
675K-
Wellington Management Group LLP Boston, MA8.98MShares$202 Million0.04% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$106 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.88MShares$87.5 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.75MShares$84.6 Million1.82% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.56MShares$80.2 Million0.01% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.05B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...